Cross-talk of cholinergic and β-adrenergic receptor signalling in chronic myeloid leukemia K562 cells.
Banu AydınMehmet Zafer GörenZehra KanlıHülya CabadakPublished in: Clinical and experimental pharmacology & physiology (2022)
In many studies on breast, skin and intestinal cancers, β-adrenergic receptor antagonists have been shown to inhibit cell proliferation and angiogenesis and increase apoptosis in cancers. Carbachol inhibits chronic myeloid leukaemia K562 cell proliferation. Beta-blockers are known to inhibit cell progression. The aim of this study is to explain the mechanism of action of β-adrenergic receptors agonists and antagonists on apoptosis in chronic myeloid leukaemia cells. We tried to determine the effect of combined treatment of β-adrenergic and cholinergic drugs on adrenergic β 1 and β 2 gene expression, cell proliferation and apoptosis in chronic myeloid leukaemia K562 cells. Cell proliferation was evaluated by the 5-bromo-2-deoxy-uridine (BrdU) incorporation kit. Caspase 3, 8, 9 activities were measured by the caspase assay kit. Protein expression level was detected by western blotting. We found that exposure to propranolol either by combination with carbachol facilitates additive effects on inhibition of caspase 3 and 8 expression in chronic myeloid leukaemia K562 cells. However, caspase 9 expression level was increased by propranolol alone or with propranolol and carbachol combination. The combined therapy of cholinergic and adrenergic receptor drugs will decrease cell proliferation in K562 cells. This decrease in cell proliferation may be mediated by the mitochondrial-dependent intrinsic apoptosis pathway.
Keyphrases
- cell cycle arrest
- induced apoptosis
- cell proliferation
- cell death
- endoplasmic reticulum stress
- pi k akt
- oxidative stress
- gene expression
- signaling pathway
- cell cycle
- dendritic cells
- bone marrow
- poor prognosis
- single cell
- stem cells
- south africa
- endothelial cells
- drug induced
- mesenchymal stem cells
- chronic myeloid leukemia
- combination therapy
- angiotensin ii